BML (BMZ) Stock Overview
Provides contract clinical testing and related services in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for BMZ from our risk checks.
BMZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BML, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥20.40 |
| 52 Week High | JP¥23.60 |
| 52 Week Low | JP¥18.40 |
| Beta | 0.23 |
| 1 Month Change | 4.62% |
| 3 Month Change | 5.70% |
| 1 Year Change | -2.86% |
| 3 Year Change | 7.37% |
| 5 Year Change | -40.11% |
| Change since IPO | 3.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| BMZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 1.0% | 1.7% | -2.3% |
| 1Y | -2.9% | -3.4% | 4.8% |
Return vs Industry: BMZ matched the German Healthcare industry which returned -2.3% over the past year.
Return vs Market: BMZ underperformed the German Market which returned 3.4% over the past year.
Price Volatility
| BMZ volatility | |
|---|---|
| BMZ Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BMZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BMZ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 4,612 | Kensuke Kondo | www.bml.co.jp |
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds.
BML, Inc. Fundamentals Summary
| BMZ fundamental statistics | |
|---|---|
| Market cap | €762.12m |
| Earnings (TTM) | €43.94m |
| Revenue (TTM) | €844.97m |
Is BMZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMZ income statement (TTM) | |
|---|---|
| Revenue | JP¥151.27b |
| Cost of Revenue | JP¥102.01b |
| Gross Profit | JP¥49.26b |
| Other Expenses | JP¥41.40b |
| Earnings | JP¥7.87b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 11, 2026
| Earnings per share (EPS) | 209.85 |
| Gross Margin | 32.57% |
| Net Profit Margin | 5.20% |
| Debt/Equity Ratio | 0% |
How did BMZ perform over the long term?
See historical performance and comparisonDividends
Does BMZ pay a reliable dividends?
See BMZ dividend history and benchmarks| BML dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2026 |
| Dividend Pay Date | Dec 02 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 77 days |
Does BMZ pay a reliable dividends?
See BMZ dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 01:28 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BML, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Yuki Yamazaki | Daiwa Securities Co. Ltd. |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |